Active Ingredient History
Plinabulin is a small molecule under development by BeyondSpring Pharmaceuticals, and is in a world-wide Phase 3 clinical trial for non-small cell lung cancer. Plinabulin is being investigated for the reduction of chemotherapy-induced neutropenia and for anti-cancer effects in combination with immune checkpoint inhibitors and in KRAS mutated tumors. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Carcinoma, Merkel Cell (Phase 1/Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 1/Phase 2)
Drug-Related Side Effects and Adverse Reactions (Phase 2/Phase 3)
Lung Neoplasms (Phase 1/Phase 2)
Melanoma (Phase 1/Phase 2)
Multiple Myeloma (Phase 2)
Mutation (Phase 1/Phase 2)
Neoplasms (Phase 1/Phase 2)
Oncogenes (Phase 1/Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Translocation, Genetic (Phase 1/Phase 2)
Urinary Bladder Neoplasms (Phase 1/Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue